Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier

被引:45
|
作者
Luker, GD
Rao, VV
Crankshaw, CL
Dahlheimer, J
PiwnicaWorms, D
机构
[1] WASHINGTON UNIV,SCH MED,DEPT RADIOL,LAB MOL RADIOPHARMACOL,ST LOUIS,MO 63110
[2] WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110
关键词
D O I
10.1021/bi971931z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The multidrug resistance (MDR1) P-glycoprotein functions as a broad specificity efflux transporter of structurally diverse natural product and xenobiotic compounds. P-glycoprotein also is an important component of the functional blood-brain barrier. To enable further studies of function and modulation of MDR1 P-glycoprotein in vitro and in vivo, two novel phosphine technetium(III) complexes were designed and characterized: trans-[2,2'-(1,2-ethanediyldiimino)bis(1,5-methoxy-5-methyl-4-oxohexenyl)]bis[methylbis(3-methoxy-1-propyl)phosphine]Tc(III) (Tc-Q58) and trans-[5,5'-(1,2-ethanediyl diimino)bis(2-ethoxy-2-methyl-3-oxo-4-pentenyl)]bis[dimethyl(3-methoxy-1-propyl)phosphine)]Tc(III) (Tc-Q63). In human drug-sensitive KB 3-1 cells and multidrug-resistant KB 8-5 and 8-5-11 derivative cell lines, expressing nonimmunodetectable, low, and high levels of MDR1 P-glycoprotein, respectively, accumulation of Tc-Q58 and Tc-Q63 was inverse to expression of the transporter. Differences between drug-sensitive and multidrug-resistant cells, while detectable at picomolar concentrations of each radiopharmaceutical, were independent of tracer concentration, Ratios of tracer accumulation in KB 3-1 and 8-5 cells were 62.3 and 48.1 for Tc-Q58 and Tc-Q63, respectively. Cell contents of Tc-Q58 and Tc-Q63 were enhanced up to 60-fold in MDR cells by known modulators of MDR1 P-glycoprotein, while drugs not in the multidrug-resistant phenotype had no effect on their accumulation. In KB 8-5 cells, potency of modulators was GF120918 much greater than cyclosporin A > verapamil. Accumulation of Tc-Q58 and Tc-Q63 in Sf9 insect cells infected with a recombinant baculovirus containing human MDR1 P-glycoprotein was reduced in a GF120918-reversible manner (EC50 less than or equal to 70 nM) compared with cells infected with a wild-type baculovirus. By contrast, cell contents of Tc-Q58 or Tc-Q63 in Sf9 cells expressing the homologous MDR3 P-glycoprotein did not differ from wild-type virus, Demonstrating molecular targeting of these complexes in vivo, distribution and retention of Tc-Q58 in brain tissue of FVB mice treated with a saturating dose of GF120918 and mice deficient in the mdr1a gene [mdr1a (-/-)] were enhanced 180% and 520% over control, respectively. Exploiting the gamma-emission spectrum of Tc-99m, increased uptake of Tc-Q58 in brain tissue of mdr1a (-/-) mice was readily detected noninvasively by scintigraphic imaging. Thus, both Tc-Q58 and Tc-Q63 are demonstrated to be substrates for transport by MDR1 P-glycoprotein, broadening the specificity of this transporter to include phosphine-containing metal complexes. As shown with Tc-Q58, these Q complexes can be used to detect transport activity and modulation of MDR1 P-glycoprotein in vitro and to directly monitor the functional status of P-glycoprotein at the blood-brain barrier in vivo.
引用
收藏
页码:14218 / 14227
页数:10
相关论文
共 50 条
  • [1] Profiling p-glycoprotein dependent multidrug resistance at the blood-brain barrier
    Bubick, M
    Fricker, G
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2005, 371 : R4 - R4
  • [2] The functional role of P-glycoprotein in the blood-brain barrier
    vanAsperen, J
    Mayer, U
    vanTellingen, O
    Beijnen, JH
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (08) : 881 - 884
  • [3] P-glycoprotein, a gatekeeper in the blood-brain barrier
    Schinkel, AH
    ADVANCED DRUG DELIVERY REVIEWS, 1999, 36 (2-3) : 179 - 194
  • [4] Blood-brain barrier function of P-glycoprotein
    Tsuji, A
    Tamai, I
    ADVANCED DRUG DELIVERY REVIEWS, 1997, 25 (2-3) : 287 - 298
  • [5] P-glycoprotein regulated transport of glutamate at blood-brain barrier
    Liu, XD
    Liu, GQ
    ACTA PHARMACOLOGICA SINICA, 2001, 22 (02): : 111 - 116
  • [6] P-Glycoprotein, a gatekeeper in the blood-brain barrier
    Division of Experimental Therapy, Netherlands Cancer Inst., P., 1066 CX Amsterdam, Netherlands
    Adv. Drug Deliv. Rev., 2-3 (179-194):
  • [7] The multidrug resistance transporter P-glycoprotein (P-gp) in the blood-brain barrier (BBB)
    Wu, Bin
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2015, 128 (03) : S189 - S189
  • [8] Modulation of p-glycoprotein transport function at the blood-brain barrier
    Bauer, B
    Hartz, AMS
    Fricker, G
    Miller, DS
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2005, 230 (02) : 118 - 127
  • [9] Detection of the multidrug resistance P-glycoprotein in healthy tissues: The example of the blood-brain barrier
    Lechardeur, D
    PhungBa, V
    Wils, P
    Scherman, D
    ANNALES DE BIOLOGIE CLINIQUE, 1996, 54 (01) : 31 - 36
  • [10] Characterization of functional assays of multidrug resistance P-glycoprotein transport activity
    Bosch, I
    Crankshaw, CL
    PiwnicaWorms, D
    Croop, JM
    LEUKEMIA, 1997, 11 (07) : 1131 - 1137